WHO SHOULD RECEIVE NOVEL HORMONAL THERAPY WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER?

Treatment with androgen deprivation (ADT) has for many years been a standard treatment for patients with metastatic hormone-sensitive prostate cancer (mHSPC). However, several phase 3 randomized trials have completely changed the therapeutic approach for these patients. First, two phase 3 trials, CH...

Full description

Saved in:
Bibliographic Details
Published inActa clinica Croatica (Tisak) Vol. 58; no. Suppl 2; pp. 69 - 72
Main Author Omrčen, Tomislav
Format Journal Article
LanguageEnglish
Published Croatia Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb 01.11.2019
Subjects
Professional Papers
Metastatic
Prostate Cancer
Hormone Sensitive
Novel Hormonal Therapy
Online AccessGet full text

Cover

More Information
Summary:Treatment with androgen deprivation (ADT) has for many years been a standard treatment for patients with metastatic hormone-sensitive prostate cancer (mHSPC). However, several phase 3 randomized trials have completely changed the therapeutic approach for these patients. First, two phase 3 trials, CHAARTED and STAMPEDE, showed that docetaxel added to ADT improves survival of patients with mHSPC. Here we present an overview of the most important trials in this setting: STAMPEDE, LATITUDE, ARCHES, ENZAMET and TITAN in which abiraterone acetate, enzalutamide and apalutamide combined with ADT achieved significant improvement in overall survival of patients with mHSPC compared with ADT only. All three agents combined with ADT became new standard of therapy for this group of patients.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0353-9466
1333-9451
DOI:10.20471/acc.2019.58.s2.11